{"preliminary_commentary":{"by_channel":{"x_thread":25,"youtube":5,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05899608\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"HARMONi-3","nct_id":"NCT05899608","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=harmoni-3-nct05899608. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subject will receive ivonescimab and chemotherapy","label":"Arm A - Ivonescimab and chemotherapy","type":"EXPERIMENTAL"},{"description":"Subject will receive pembrolizumab and chemotherapy","label":"Arm B - Pembrolizumab and chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":1600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivonescimab Injection","otherNames":[],"type":"BIOLOGICAL"},{"name":"Pembrolizumab Injection","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-10-08","lead_sponsor":"Summit Therapeutics","official_title":"A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"approximately 4 years"},{"measure":"Progression Free Survival (PFS)","timeFrame":"approximately 3 years"}],"references":[],"start_date":{"date":"2023-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","url":"https://clinicaltrials.gov/study/NCT05899608"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/harmoni-3-nct05899608"}